The Crusaders have continued their perfect start to the Super Rugby Aotearoa season by beating the Hurricanes 33-16 at Orangetheory Stadium.
The Crusaders have continued their perfect start to the Super Rugby Aotearoa season by beating the Hurricanes 33-16 at Orangetheory Stadium.
Deep Lens and Alabama Oncology today announced that they have entered into a partnership that will integrate Deep Lens’ artificial-intelligence (AI)-based clinical trial matching solution, VIPER™, into all offices within the Alabama Oncology network. VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. Alabama Oncology is one of the largest community based hematology / oncology practice groups in the state and utilizes the Cardinal Health Specialty Solutions network’s distribution and technology solutions. Alabama Oncology is one of the first to deploy VIPER since the launch of Cardinal Health™ Navista™ TS (Tech Solutions), a comprehensive and integrated suite of oncology-focused tech solutions designed to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care.
Home prices across the United States rose in the first three months of the year at an annualized rate of 9.3 percent, according to Radian Home Price Index (HPI) data released today by Red Bell Real Estate, LLC, a Radian Group Inc. company (NYSE: RDN). The company believes the Radian HPI is the most comprehensive and timely measure of U.S. housing market prices and conditions available in the market today.
Bulk Data Centers Joins the Sustainable Digital Infrastructure Alliance (SDIA), further committing toward zero-emissions.
Katy Daley-McLean says the tantalising prospect of this weekend’s Six Nations Final means there’s no better time for women and girls to give rugby a go.
Stellantis on Thursday launched its first fully electric large van, the Fiat e-Ducato, as part of its bid to expand its range of battery electric and hybrid vehicles. Stellantis has said it would offer electric versions of almost all of its European line-up by 2025, as the auto industry faces regulatory pushes in Europe and China to accelerate the shift to zero-emission vehicles. The e-Ducato, which has a range of around 370 km (230 miles) on a single charge, is already available for orders to clients and will be followed this year by other similar large vans produced by Stellantis under the Peugeot, Opel and Citroen brands.
The deepening disparities between two of the world’s largest countries should remind optimistic Americans that with light at the end of their own tunnel, it’s probably time for the U.S. to start thinking about how it can help end the pandemic elsewhere too.
PPG (NYSE:PPG) today announced that it again achieved a Gold Rating in corporate social responsibility from EcoVadis, a leading provider of business sustainability ratings. Only 6% of evaluated companies met the qualifications for a Gold Rating.
SixSurgery, a leading cosmetic surgery centre led by Dr. Martin Jugenburg has always been ahead of the curve when it comes to surgical techniques, safety, and patient care. And now, in 2021, they are about to take it one step further.Toronto, April 22, 2021 (GLOBE NEWSWIRE) -- As Bitcoin breaks all-time highs, people are increasingly becoming more open to accepting Bitcoin as payment for goods and services while discovering various use cases and benefits. Dr. Martin Jugenburg, founder of SixSurgery and popularly known as 'Dr. Six' is leading the trend as the first plastic surgeon in Canada to accept cryptocurrency as payment for products, services, and full surgical procedures. Dr. Jugenburg is no stranger to challenging norms. As one of the first in Canada to introduce social media as a medium for patient awareness and education, he found an unconventional way to break down barriers between patients and doctors through streaming authentic journeys. Now, Dr. Jugenburg is renowned for releasing daily content that redefine realistic expectations and allow for patients to engage in the process, having a community of plastic surgeons follow suit. Admitting that accepting bitcoin can seem like a “leap of faith” with the volatility, Dr. Jugenburg sees that as a price he’s willing to pay for the plausible benefits, a critical one being privacy: “Many of my clients come from the Middle East, including Saudi Arabia and Kuwait, which are places that are still very traditional and consider it crucial to keep their visit completely private. For surgeries such as Hymen Reconstruction and Labiaplasties, the privacy that needs to be maintained could lead to extreme consequences. Alternatively in North America, natural breasts are one of the most sought out procedures. We started to accept Bitcoin, mainly because this allowed our clients to not have a transaction statement that their parents or significant others could easily discover.” Bitcoin is exchanged using blockchain technology, making payment with cryptocurrency virtually untraceable. Aside from the privacy related benefits, the jump to accepting cryptocurrency is also largely due to the fact that it allows Dr. Jugenburg to serve patients globally, and accept payment anywhere. By using CoinBase commerce to manage the transactions and Cointracker to track payments and taxes, Dr. Jugenburg and the SixSurgery team are eager to migrate to a system without the hassle of wires, multiple currencies, or third party fees. Conversion rates are tracked in real time leaving the transaction posted on a public ledger using private addresses, having the potential to mitigate credit card fraud. When asked if he thinks that more Canadian cosmetic surgery clinics will start accepting cryptocurrency, Dr. Jugenburg explains “In business you have to take risks. Being the first is never easy, but it needs to happen. I have no doubt as the technology matures and an ecosystem is built, that this unfamiliar territory has the potential to transform the healthcare industry all together. For it to work, there needs to be mass adoption and if businesses don’t start adopting it, they may be left behind.” As a believer in the future of cryptocurrency, Dr. Jugenburg plans to hold assets in cryptocurrency following suit of some of the large corporations like MicroStrategy and Tesla that are buying Bitcoin for their balance sheets. If interested in a cosmetic procedure using cryptocurrency, learn more at https://torontosurgery.com/fees-financing-cosmetic-surgery/ About SixSurgery SixSurgery is a team of top tier surgeons at the Toronto Cosmetic Surgery Institute hand-selected by Dr. Martin Jugenburg for their achievements, professionalism, and outstanding results in their respective fields. With their extensive training, natural skill, and combined experience in all aspects of cosmetic surgery, they are dedicated to giving world-class surgical care and the best possible aesthetic results. -Article crafted using AI-Powered copywriter, Craftly.ai CONTACT: Iman Bashir Craftly.AI 4165004939 email@example.com
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Rating of "a" of Tokio Marine GRV Re, Inc. (TMGRV Re) (Oklahoma City, OK). The outlook of these Credit Ratings (ratings) is stable.
Detroit, April 22, 2021 (GLOBE NEWSWIRE) -- SmithGroup, one of the nation’s leading integrated design firms, has initiated partnerships with architecture programs at three historically Black universities – Florida A&M University (Tallahassee, Fl.), Hampton University (Hampton, Va.) and Howard University (Washington, D.C.). SmithGroup has formed a five-year partnership with each of the participating institutions which includes financial support to each school for programming needs, an internship program and academic mentorship. The intent of the partnership program is to increase the number of architecture degrees awarded to Black students, thereby contributing to the development of a more diverse design talent pipeline. SmithGroup’s promise to Design a Better Future includes a commitment to creating a more diverse profession, through supporting underrepresented populations in the design industry. Black architects are historically underrepresented in the architecture profession. In 2019, the National Architectural Accrediting Board (NAAB) reported that only 4% of the degrees awarded that year were to African American students. “We formulated the HBCU partnership program with three goals in mind: to address equity through sponsorships, diversity through internships, and inclusion through academic mentorship,” says Taft Cleveland, an architectural designer at the Chicago office of SmithGroup. Cleveland, an alumnus of Florida A&M University School of Architecture and Engineering Technology, initiated the partnership program and is overseeing its growth. The seven HBCUs offering NAAB accredited architecture programs award 32% of the architecture degrees earned by Black architecture students in the United States, according to the Association of Collegiate Schools of Architecture. Through targeted partnership with architecture programs at HBCUs, SmithGroup hopes to address some of the inequities facing Black architecture students today, increasing the number of graduates. SmithGroup worked directly with architecture faculty at each university to craft meaningful engagement in the coursework of each institution. SmithGroup employees are participating in bi-weekly virtual desk crits providing real-time feedback and mentorship as students advance through their coursework. Staff will also serve as jurors for the program’s midterm and/or final projects. SmithGroup is also selecting students from each of the three universities for paid summer internships with the firm’s Chicago, Detroit or Washington, D.C. offices to provide practical learning opportunities in a real-world setting. Select architectural and engineering staff are lecturing at each university, teaching students a well-rounded understanding of how architects collaborate with other design disciplines, how successful businesses operate, tools used in delivering design work today, and leadership and collaboration skills needed to be successful in the field today. “The SmithGroup partnership is supporting our third-year studios, which are focusing on housing. The firm’s staff, some of whom graduated from Howard, are complementing our studio instructors, and are bringing expertise specific to the studio project. It has been a great experience for our students, and we look forward to continuing the partnership,” says Dr. Hazel Edwards, Professor and Chair in the Department of Architecture in the College of Engineering and Architecture at Howard University. In addition to the intensive academic mentorship of this partnership program, SmithGroup’s annual Equity, Diversity and Inclusion scholarship program has provided students from historically underrepresented demographics in architecture, interior design, planning, landscape architecture or engineering programs financial support and internship experiences since its inception in 2018. SmithGroup also fundraised to provide students in Howard University’s Department of Architecture program with personal laptops to aid in their studies, alleviating one hardship many students in the program faced when COVID-19 closed their campus. Read more about SmithGroup’s commitment to Justice, Equity, Diversity and Inclusion and our statement on Racial Injustice and Action. SmithGroup (www.smithgroup.com) is one of the world’s preeminent integrated design firms. Working across a network of 15 offices in the U.S. and China, a team of 1,200 experts is committed to excellence in strategy, design and delivery. The firm partners with forward-looking clients to maximize opportunities, minimize risk and solve their most complex problems. SmithGroup creates exceptional design solutions for healthcare, science and technology organizations, higher education and cultural institutions, urban environments, diverse workplaces, mixed-use and waterfront developments, and parks and open spaces. Attachment SmithGroup HBCU Partnership NR CONTACT: Dave Whitman SmithGroup 313.442.8226 firstname.lastname@example.org
Exxon Mobil said it has expanded an agreement to buy more renewable diesel from Global Clean Energy's biorefinery in Bakersfield, California, as climate policies pressure companies to cut their carbon emissions and opt for cleaner fuels. The largest U.S. oil producer has been facing pressure from environmentalists and investors to do more for climate change and for the first time, it reported emissions from burning its fuels such as gasoline and jet fuel earlier this year. Earlier this month, the Treasury Department released details of a tax hike proposal that would replace subsidies for fossil fuel companies with incentives for production of clean energy under President Joe Biden's infrastructure plan.
The "Cold Chain Packaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Epic Games Store has added multiple apps, including the indie game shop Itch.io and Brave's browser.
You can take out a personal loan to pay for almost anything you want. Wedding loans are marketed to people looking for help paying for their nuptials. The only problem is, wedding loans make an already expensive event even more costly.
Existing home sales fell 3.7% to a seasonally adjusted 6.01 million in March, from a month earlier, according to the National Association of Realtors (NAR), which revised Febraury existing home sales to 6.24 million.
U.S. home sales fell to a seven-month low in March, pulled down by an acute shortage of properties, which is boosting prices and making owning a house more expensive for some first-time buyers. Existing home sales dropped 3.7% to a seasonally adjusted annual rate of 6.01 million units last month, the lowest level since August 2020, the National Association of Realtors said on Thursday. Existing home sales, which are counted at the closing of a contract, lag signings by a month or two.
Following its groundbreaking merger with Brinker Capital and strategic acquisition of HiddenLevers, Orion Advisor Solutions has assembled a new team of growth and marketing executives to fuel its ongoing innovations to win new business.
− Harmony Study began dosing patients who are allergic to one food or to multiple foods in a Phase 1/2 clinical trial – − ADP101 is an investigational oral immunotherapy product candidate representing the nine food groups responsible for the vast majority of significant food allergic reactions − MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private biopharmaceutical company focused on developing novel prescription therapeutics for food allergy, today announced that the first patients have been dosed in The Harmony Study, a first-in-human Phase 1/2 clinical trial to evaluate ADP101 for the treatment of food allergy. “Alladapt’s lead program is based on more than a decade of research and clinical studies demonstrating that food allergic patients have the potential to achieve desensitization across all major allergenic food groups and that this can be accomplished whether patients are mono- or multi-food-allergic,“ said Ashley Dombkowski, PhD, Alladapt’s Chief Executive Officer and co-founder. “The initiation of this clinical trial is a significant milestone underscoring our unwavering commitment to developing novel oral medicines capable of addressing food allergic disease triggered by an expansive set of antigens.” Kari Nadeau, MD, PhD, scientific inventor of ADP101 and co-founder of Alladapt emphasized, “We need FDA-approved medicines that can address food allergy and help desensitize as many patients as possible. Food allergy is associated with a remarkably diverse set of foods, and patients are increasingly multi-allergic. For these reasons, I am excited that ADP101, a standardized, multi-allergen, oral immunotherapeutic agent, is now being evaluated in patients through the FDA-regulated clinical trials process.” The Harmony Study is a Phase 1/2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ADP101 for oral immunotherapy (OIT) in children and adults diagnosed with allergy to either one food or to multiple foods from a set of the most commonly allergenic foods. The Harmony Study plans to enroll patients across 20 sites in the United States. “With the initiation of the ADP101 clinical program, we are honored to collaborate with leading allergy clinics and food allergy patients across the United States,” said Dana McClintock, MD, Chief Medical Officer at Alladapt. “The rigorous design of our Phase 1/2 Harmony Study was informed by the growing body of clinical data from oral immunotherapy studies around the world. Our study has been further supported by bioinformatics analyses, including insights from large epidemiology data sets along with in silico evaluation of allergenic protein structures.” “Food allergy is a serious, unpredictable, widespread disease that not only causes severe reactions but also places disabling and chronic limitations on the lives of patients and their families,” said Daniel H. Petroni, MD, PhD, Executive Director of the Seattle Allergy & Asthma Research Institute and Director of the Northwest Food Allergy Treatment & Research Center. “As one of the first clinical sites enrolling patients in the Harmony Study, we are delighted to participate in a study designed to assess the efficacy and safety of an intervention with the potential to broadly treat the most common causes of food allergy.” About ADP101 and Oral ImmunotherapyADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy to one or more foods. ADP101 is formulated to consistently deliver a well-characterized investigational drug product sourced from the most commonly allergenic food groups and designed to be administered as part of a clinically monitored dosing protocol. The goal of oral immunotherapy is to induce a state of clinically meaningful desensitization to food proteins, defined as the absence of moderate or severe allergic reaction following the ingestion of small but potentially dangerous amounts of food. About Food AllergyFood allergy is a serious disease posing significant challenges for affected patients and families ranging from social isolation and anxiety to potentially life-threatening consequences from inadvertent exposure. Food allergy affects 32 million people in the United States alone and it is estimated that 240 million to 550 million are affected by food allergy worldwide.1, 2, 3 There are 9 food groups responsible for 90 percent of food allergic reactions.4 Of the food allergy-related emergency department visits in the U.S. in a single year, 15 times as many were reported in patients with at least one non-peanut allergy versus those who report food allergy to peanut alone.1,2, 5 Furthermore, of patients with food allergy, 30-60 percent are multi-allergic, which can increase the relative risk of reactions from accidental exposures by several fold.1, 2, 6 There are no FDA-approved therapies for the vast majority of patients. About Alladapt ImmunotherapeuticsAlladapt Immunotherapeutics is a private, clinical-stage biopharmaceutical company developing prescription therapeutics targeting food allergy. Alladapt was co-founded in 2018 by allergist and protein biochemist Kari Nadeau, MD, PhD and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure under tightly controlled clinical supervision to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms, pathways, and protein structures, led the founders to envision biopharmaceutical interventions capable of addressing food allergy provoked by a wide-ranging set of antigens. Gurnet Point Capital, a private investment firm focused on the healthcare and life sciences sectors, is Alladapt’s primary investor. For more information, please visit the Company's website at www.alladapt.com. References1 Gupta, R. S., Warren, C. M., Smith, B. M., Jiang, J., Blumenstock, J. A., Davis, M. M., et al. (2019). "Prevalence and Severity of Food Allergies Among US Adults." JAMA Netw Open 2(1): e185630. 2 Gupta, R. S., Warren, C. M., Smith, B. M., Blumenstock, J. A., Jiang, J., Davis, M. M., et al. (2018). "The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States." Pediatrics 142(6). 3 Fiocchi A, Sampson HA, Bahna SL, Lack G. “Food Allergy”, Section 2.6 in WAO White Book on Allergy: Update 2013, edited by R Pawankar, GW Canonica, ST Holgate, RF Lockey, and MS Blaiss, World Allergy Organization, 2014. 4 Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011;31(1):61-75. doi:10.1016/j.nutres.2011.01.001. 5 Warren C, Lei D, Sicherer S, Schleimer R, Gupta R. Prevalence and characteristics of peanut allergy in US adults. Journal of Allergy and Clinical Immunology. 2021 Feb 9. 6 Kapoor, S., Roberts, G., Bynoe, Y., Gaughan, M., Habibi, P. and Lack, G. (2004), Influence of a multidisciplinary paediatric allergy clinic on parental knowledge and rate of subsequent allergic reactions. Allergy, 59: 185-191. Source: Alladapt Immunotherapeutics, Inc. CONTACT: Contact Information: Alladapt Immunotherapeutics | email@example.com
NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Romeo Power, Inc. ("Romeo" or "the Company") (NYSE: RMO), formerly known as RMG Acquisition Corp. (“RMG”) (NYSE: RMG), and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Romeo securities between October 2, 2020 and March 30, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/rmo. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On March 30, 2021, Romeo issued a press release announcing its financial and operating results for the fourth quarter of 2020. With respect to its 2021 outlook, citing “supply constraints” and “the significant shortfall in battery cell capacity industrywide,” Romeo advised investors that is “now expects its revenue for 2021 to be in the range of $18-40 million”—significantly lower than analyst expectations. On this news, Romeo’s stock price fell $2.04 per share, or 19.67%, to close at $8.33 per share on March 31, 2021. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) it was suffering from an acute shortage of high-quality battery cells, which are key raw materials for Romeo's battery packs and modules, due to supply constraints. Contrary to Defendants' representations, (2) Romeo had only two battery cell suppliers, not four, (3) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and prospects, (4) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (5) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (6) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/rmo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Romeo you have until June 15, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes. Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz 212-697-6484 | firstname.lastname@example.org
Spruce Point Capital Management, LLC ("Spruce Point" or "we" or "us"), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled "When The Tide Goes Out, What Will Wash Ashore?" that outlines why shares of Danimer Scientific, Inc. (NYSE: DNMR) ("Danimer" or the "Company"), face up to 65% downside risk and 100% long-term downside risk. Download or view the report by visiting www.SprucePointCap.com and follow us on Twitter @SprucePointCap for additional information and exclusive updates.